Literature DB >> 21916825

Quality of life: the ultimate outcome measure of interventions in major depressive disorder.

Waguih William IsHak1, Jared Matt Greenberg, Konstantin Balayan, Nina Kapitanski, Jessica Jeffrey, Hassan Fathy, Hala Fakhry, Mark Hyman Rapaport.   

Abstract

BACKGROUND: Quality-of-life (QOL) assessment and improvement have recently been recognized as important components of health care, in general, and mental health care, in particular. Patients with major depressive disorder (MDD) have a significantly diminished QOL.
METHODS: Using a Medline search of relevant keywords for the past 26 years, this article reviews the empirical literature to provide information regarding QOL measurement, impairment, impact of comorbidity, and treatment effects in MDD.
RESULTS: Studies showed that QOL is greatly affected by depression. Severity of depression is also a major contributor to further reduction in QOL when depression is comorbid with other psychiatric and medical disorders. Treatment for MDD has been shown to improve QOL in the acute treatment phase, but QOL remains low compared to healthy controls even when symptoms are in remission following treatment.
CONCLUSIONS: Patients with MDD suffer from poor QOL even after reduction of symptom severity. Clinicians should therefore include QOL assessment as an important part of treating depression. More research is needed to examine the factors contributing to poor QOL in MDD and to develop interventions to ameliorate it. Additionally, future treatment studies of MDD with or without comorbid disorders should track QOL as the ultimate outcome measure of treatment success.

Entities:  

Mesh:

Year:  2011        PMID: 21916825     DOI: 10.3109/10673229.2011.614099

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  65 in total

Review 1.  Utility scores for different health states related to depression: individual participant data analysis.

Authors:  Spyros Kolovos; Judith E Bosmans; Johanna M van Dongen; Birre van Esveld; Dorcas Magai; Annemieke van Straten; Christina van der Feltz-Cornelis; Kirsten M van Steenbergen-Weijenburg; Klaas M Huijbregts; Harm van Marwijk; Heleen Riper; Maurits W van Tulder
Journal:  Qual Life Res       Date:  2017-03-04       Impact factor: 4.147

2.  Cortisol, oxytocin, and quality of life in major depressive disorder.

Authors:  Ai Ling Tang; Susan J Thomas; Theresa Larkin
Journal:  Qual Life Res       Date:  2019-06-21       Impact factor: 4.147

3.  Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up.

Authors:  W W IsHak; J Mirocha; D James; G Tobia; J Vilhauer; H Fakhry; S Pi; E Hanson; R Nashawati; E D Peselow; R M Cohen
Journal:  Acta Psychiatr Scand       Date:  2014-06-23       Impact factor: 6.392

4.  The association of alcohol use and quality of life in depressed and non-depressed individuals: a cross-sectional general population study.

Authors:  Jonna Levola; Tuuli Pitkänen; Olli Kampman; Mauri Aalto
Journal:  Qual Life Res       Date:  2017-11-29       Impact factor: 4.147

5.  IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY.

Authors:  Tracy L Greer; Joseph M Trombello; Chad D Rethorst; Thomas J Carmody; Manish K Jha; Allen Liao; Bruce D Grannemann; Heather O Chambliss; Timothy S Church; Madhukar H Trivedi
Journal:  Depress Anxiety       Date:  2016-05-10       Impact factor: 6.505

6.  Anhedonia is central for the association between quality of life, metacognition, sleep, and affective symptoms in generalized anxiety disorder: A complex network analysis.

Authors:  Abigail L Barthel; Megan A Pinaire; Joshua E Curtiss; Amanda W Baker; Mackenzie L Brown; Susanne S Hoeppner; Eric Bui; Naomi M Simon; Stefan G Hofmann
Journal:  J Affect Disord       Date:  2020-09-02       Impact factor: 4.839

7.  Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression.

Authors:  Drishti Shah; Varun Vaidya; Amit Patel; Mary Borovicka; Monica-Holiday Goodman
Journal:  Qual Life Res       Date:  2016-09-26       Impact factor: 4.147

Review 8.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care.

Authors:  Raymond W Lam; Diane McIntosh; JianLi Wang; Murray W Enns; Theo Kolivakis; Erin E Michalak; Jitender Sareen; Wei-Yi Song; Sidney H Kennedy; Glenda M MacQueen; Roumen V Milev; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

9.  Improvement in self-reported quality of life with cognitive therapy for recurrent major depressive disorder.

Authors:  Manish Kumar Jha; Abu Minhajuddin; Michael E Thase; Robin B Jarrett
Journal:  J Affect Disord       Date:  2014-06-02       Impact factor: 4.839

10.  Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial.

Authors:  Waguih William IsHak; James Mirocha; Scott Christensen; Fan Wu; Richard Kwock; Joseph Behjat; Sarah Pi; Araks Akopyan; Eric D Peselow; Robert M Cohen; David Elashoff
Journal:  Depress Anxiety       Date:  2013-07-16       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.